Biomarx, a Glasgow-based deeptech company developing next-generation genomic laboratory medicine tools, has closed a £700,000 Pre-Seed investment round. The funding was led by SFC Capital and Clarendon Fund Managers, with contributions from the University of Strathclyde, angel investors, InterTradeIreland Seedcorn Competition, and Techstart Ventures Proof of Concept Grant.
The capital will support the transition from proof of concept to MVP, pursue ISO 13485 accreditation, and conduct a preliminary lab-based clinical study — essential steps toward market entry. Development will continue in Glasgow, leveraging the University of Strathclyde’s ecosystem for deeptech commercialisation, with guidance from Prof Damion Corrigan, Dr Catherine Breslin, and Anne Henderson, CA.
Biomarx is creating automated platforms for rapid, low-cost detection of circulating tumour DNA fragments, reducing complexity and skill barriers associated with next-generation sequencing. The first product, a non-small cell lung cancer liquid biopsy test, aims to enable earlier detection and support targeted therapies.
“This funding enables Biomarx to advance critical milestones on the path to market,” said the Biomarx team. “Our mission is to accelerate clinical adoption of genomic medicine and reduce health inequalities.”